• Find People
  • Campus Map
  • PiratePort
  • A-Z
    • About
    • Submit
    • Browse
    • Login
    View Item 
    •   ScholarShip Home
    • Division of Health Sciences
    • Brody School of Medicine
    • Microbiology and Immunology
    • View Item
    •   ScholarShip Home
    • Division of Health Sciences
    • Brody School of Medicine
    • Microbiology and Immunology
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of The ScholarShipCommunities & CollectionsDateAuthorsTitlesSubjectsTypeDate SubmittedThis CollectionDateAuthorsTitlesSubjectsTypeDate Submitted

    My Account

    Login

    Statistics

    View Google Analytics Statistics

    GSK-3 as potential target for therapeutic intervention in cancer

    Thumbnail
    View/ Open
    oncotarget-05-2881.PMC4102778.pdf (4.739Mb)

    Show full item record
    Author
    McCubrey, James A.; Steelman, Linda S.; Bertrand, Fred E.; Davis, Nicole Marie; Sokolosky, Melissa; Abrams, Stephen L.; Montalto, Giuseppe; D'Assoro, Antonino B.; Libra, Massimo; Nicoletti, Ferdinando; Maestro, Roberta; Basecke, Jorg; Rakus, Dariusz; Gizak, Agnieszka; Demidenko, Zoya N.; Cocco, Lucio; Martelli, Alberto M.; Cervello, Melchiorre
    Abstract
    The serine/threonine kinase glycogen synthase kinase-3 (GSK-3) was initially identified and studied in the regulation of glycogen synthesis. GSK-3 functions in a wide range of cellular processes. Aberrant activity of GSK-3 has been implicated in many human pathologies including: bipolar depression, Alzheimer's disease, Parkinson's disease, cancer, non-insulin-dependent diabetes mellitus (NIDDM) and others. In some cases, suppression of GSK-3 activity by phosphorylation by Akt and other kinases has been associated with cancer progression. In these cases, GSK-3 has tumor suppressor functions. In other cases, GSK-3 has been associated with tumor progression by stabilizing components of the beta-catenin complex. In these situations, GSK-3 has oncogenic properties. While many inhibitors to GSK-3 have been developed, their use remains controversial because of the ambiguous role of GSK-3 in cancer development. In this review, we will focus on the diverse roles that GSK-3 plays in various human cancers, in particular in solid tumors. Recently, GSK-3 has also been implicated in the generation of cancer stem cells in various cell types. We will also discuss how this pivotal kinase interacts with multiple signaling pathways such as: PI3K/PTEN/Akt/mTORC1, Ras/Raf/MEK/ERK, Wnt/beta-catenin, Hedgehog, Notch and others.
    URI
    http://hdl.handle.net/10342/5659
    Subject
     GSK-3; cancer stem cells; Wnt/beta-catenin; PI3K; Akt; mTOR; Hedgehog; Notch; Targeted Therapy; Therapy Resistance; Mutations; Rapamycin 
    Date
    2014-05
    Citation:
    APA:
    McCubrey, James A., & Steelman, Linda S., & Bertrand, Fred E., & Davis, Nicole Marie, & Sokolosky, Melissa, & Abrams, Stephen L., & Montalto, Giuseppe, & D'Assoro, Antonino B., & Libra, Massimo, & Nicoletti, Ferdinando, & Maestro, Roberta, & Basecke, Jorg, & Rakus, Dariusz, & Gizak, Agnieszka, & Demidenko, Zoya N., & Cocco, Lucio, & Martelli, Alberto M., & Cervello, Melchiorre. (May 2014). GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget, (5:10), p.2881-2911. Retrieved from http://hdl.handle.net/10342/5659

    Display/Hide MLA, Chicago and APA citation formats.

    MLA:
    McCubrey, James A., and Steelman, Linda S., and Bertrand, Fred E., and Davis, Nicole Marie, and Sokolosky, Melissa, and Abrams, Stephen L., and Montalto, Giuseppe, and D'Assoro, Antonino B., and Libra, Massimo, and Nicoletti, Ferdinando, and Maestro, Roberta, and Basecke, Jorg, and Rakus, Dariusz, and Gizak, Agnieszka, and Demidenko, Zoya N., and Cocco, Lucio, and Martelli, Alberto M., and Cervello, Melchiorre. "GSK-3 as potential target for therapeutic intervention in cancer". Oncotarget. 5:10. (2881-2911.), May 2014. February 27, 2021. http://hdl.handle.net/10342/5659.
    Chicago:
    McCubrey, James A. and Steelman, Linda S. and Bertrand, Fred E. and Davis, Nicole Marie and Sokolosky, Melissa and Abrams, Stephen L. and Montalto, Giuseppe and D'Assoro, Antonino B. and Libra, Massimo and Nicoletti, Ferdinando and Maestro, Roberta and Basecke, Jorg and Rakus, Dariusz and Gizak, Agnieszka and Demidenko, Zoya N. and Cocco, Lucio and Martelli, Alberto M. and Cervello, Melchiorre, "GSK-3 as potential target for therapeutic intervention in cancer," Oncotarget 5, no. 10 (May 2014), http://hdl.handle.net/10342/5659 (accessed February 27, 2021).
    AMA:
    McCubrey, James A., Steelman, Linda S., Bertrand, Fred E., Davis, Nicole Marie, Sokolosky, Melissa, Abrams, Stephen L., Montalto, Giuseppe, D'Assoro, Antonino B., Libra, Massimo, Nicoletti, Ferdinando, Maestro, Roberta, Basecke, Jorg, Rakus, Dariusz, Gizak, Agnieszka, Demidenko, Zoya N., Cocco, Lucio, Martelli, Alberto M., Cervello, Melchiorre. GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget. May 2014; 5(10) 2881-2911. http://hdl.handle.net/10342/5659. Accessed February 27, 2021.
    Collections
    • Microbiology and Immunology

    xmlui.ArtifactBrowser.ItemViewer.elsevier_entitlement

    East Carolina University has created ScholarShip, a digital archive for the scholarly output of the ECU community.

    • About
    • Contact Us
    • Send Feedback